La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genovis AB (publ.) Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fredrik Olsson

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	9.4yrs
Proprietà del CEO	n/a
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	4.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Fredrik Olsson

9.4yrs

Mandato

Mr. Fredrik Olsson has been a Director of SEQURNA AB since July 2024. He has been the Chief Executive Officer of Genovis AB since May 05, 2015 and also serves as its President. Mr. Olsson served as Preside...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Fredrik Olsson	President & CEO	9.4yrs	Nessun dato	Nessun dato
Magnus Langberg	Group Chief Financial Officer	2.8yrs	Nessun dato	0.011% € 14.5k
Rikke Rytter	Vice President of Sales & Marketing	2.8yrs	Nessun dato	0.0042% € 5.5k
Maria Edholm	Controller	no data	Nessun dato	Nessun dato
John Lindsay	President of Genovis Inc.	no data	Nessun dato	Nessun dato

2.8yrs

Durata media

Gestione esperta: Il team dirigenziale di 5GV è considerato esperto (durata media dell'incarico 2.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Torben Jorgensen	Independent Chairman of the Board	4.4yrs	SEK 386.00k	0.18% € 229.9k
Charlotta Ljungqvist	Independent Director	5.4yrs	SEK 230.00k	0.0079% € 10.3k
Mikael Lonn	Director	10.8yrs	SEK 193.00k	14.5% € 18.9m
Magnus Gustafsson	Independent Director	2.4yrs	SEK 230.00k	0.017% € 21.9k
Steve Jordan	Independent Director	3.4yrs	SEK 175.00k	Nessun dato

4.4yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 5GV sono considerati esperti (durata media dell'incarico 4.3 anni).

Genovis AB (publ.) Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Genovis AB (publ.), Annual General Meeting, May 15, 2024

Director recently sold €2.2m worth of stock

Genovis AB (Publ.) Announces Board Changes

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought €5.0k worth of stock

Insider recently bought €5.0k worth of stock

Recent updates

Genovis AB Launches Fabricator® Xtra

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Second quarter 2024 earnings released: EPS: kr0.027 (vs kr0.23 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022)

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022)

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: kr0.048 (vs kr0.087 in 3Q 2022)

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Director recently sold €2.2m worth of stock

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021)

Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021)

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: kr0.01 (vs kr0.016 in 2Q 2021)

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Genovis AB (Publ.) Announces Board Changes

First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021)

Full year 2021 earnings released: EPS: kr0.38 (vs kr0.099 in FY 2020)

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought €5.0k worth of stock

Insider recently bought €5.0k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS kr0.013 (vs kr0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.016 (vs kr0.023 loss in 2Q 2020)

General Counsel recently bought €20k worth of stock

First quarter 2021 earnings released: EPS kr0.011 (vs kr0.031 loss in 1Q 2020)

Full year 2020 earnings released: EPS kr0.099 (vs kr0.15 in FY 2019)

Revenue beats expectations

New 90-day high: €4.62

Genovis AB (publ.) to Report Nine Months, 2021 Results on Nov 11, 2021

New 90-day high: €3.46

Genovis AB and Glykos Finland Oy Partner to Enable New ADC Platform

Revenue misses expectations

Third quarter 2020 earnings released: EPS kr0.02

Genovis AB (publ.), Annual General Meeting, May 20, 2021

New 90-day low: €2.95

Genovis AB (publ.) to Report First Half, 2021 Results on Aug 12, 2021

Earnings released

Genovis AB (publ) (OM:GENO) completed the acquisition of QED Bioscience, Inc.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media